# KEYNOTE-407 (NCT03875092)

> A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03875092
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Non-small Cell Lung Cancer
- Interventions: Pembrolizumab; Paclitaxel; Carboplatin; Saline placebo for pembrolizumab
- Enrollment: 125
- Primary outcome: Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
- Primary outcome: Overall Survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Podcasts: 24
- YouTube: 18
- X threads: 18

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=keynote-407-nct03875092

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03875092", "email": "<work email>"}; the inbox owner confirms by the emailed link.